论文部分内容阅读
肝海绵状血管瘤是肝脏最常见的良性肿瘤,近年来检出率逐年增高。随着介入和微创等技术的发展,目前针对肝海绵状血管瘤的临床治疗展现出多元化、个体化、综合化和微创化的趋势。然而由于一些医师对肝海绵状血管瘤的发展及治疗原则认识不足,也随之带来一系列诸如治疗指征过宽、风险评估不足、治疗方法选择不当等问题。因此如何规范肝海绵状血管瘤的治疗、使病人达到最佳的风险效益比,已经成为当前迫切需要解决的重要问题。
Liver cavernous hemangioma is the most common benign liver tumors, the detection rate increased year by year in recent years. With the development of interventional and minimally invasive techniques, the clinical treatment of hepatic cavernous hemangiomas is diversified, individualized, integrated and minimally invasive. However, due to lack of knowledge about the development and treatment of hepatic cavernous hemangiomas, some physicians also bring a series of problems such as extensive indications for treatment, inadequate risk assessment and improper treatment options. Therefore, how to standardize the treatment of hepatic cavernous hemangiomas so that patients achieve the best risk-benefit ratio has become an urgent issue that needs urgent solution.